Ready-Made immune cells take on lymphoma and leukemia in first human trial
Disease control
Not yet recruiting
This early-phase study tests ALA-101, a pre-made cell therapy that targets CD19 on cancer cells, in adults with certain types of non-Hodgkin lymphoma or leukemia. The main goal is to check safety and find the best dose. About 46 participants will receive the treatment and be moni…
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated May 04, 2026 03:00 UTC